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TECHNICAL NOTE
Effects of carboxy-terminal modifications of proteinase 3 (PR3)
on the recognition by PR3-ANCA
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Effects of carboxy-terminal modifications of proteinase 3 (PR3) trophil proteinase 3 (PR3) is the principle target antigen
on the recognition by PR3-ANCA. for C-ANCA [3].
Background. Autoantibodies directed against neutrophil The neutrophil serine proteases including PR3 are sub-proteinase 3 (PR3-ANCA) from patients with Wegener’s gran-
ject to post-translational processing prior to being storedulomatosis and microscopic polyangiitis recognize conforma-
in granules in their mature form. The product of PR3tional epitopes of PR3. During maturation of neutrophils, PR3
undergoes amino-terminal and carboxy-terminal processing. In mRNA translation is a preproenzyme that undergoes three
contrast to amino-terminal processing, the effects of carboxy- subsequent proteolytic modifications: cleavage of the sig-
terminal processing on recognition of PR3 by PR3-ANCA
nal peptide, of the amino-terminal pro-dipeptide Ala-remain unknown. Carboxy-terminally modified or tagged re-
Glu, and of a carboxy-terminal pro-heptapeptide [4–6].combinant PR3 (rPR3) molecules may be useful for the re-
finement of diagnostic assays and for the study of biological Proteinase 3 recognition by PR3-ANCA depends upon
processes. the preservation of conformational epitopes [7]. Amino-
Methods. This study was designed to determine whether terminal processing of the PR3 molecule critically affects293 cells can be used to express specifically designed carboxy-
recognition by a subset of PR3-ANCA, which may corre-terminal variants of rPR3, and to evaluate the effects of differ-
late with disease activity [8, 9]. Unlike the conformationalent carboxy-terminal modifications on the recognition by PR3-
ANCA in the capture ELISA. and functional effects of amino-terminal processing of
Results. The rPR3-variants secreted into the media superna- PR3, the physiologic significance and effects of carboxy-
tants of transfected 293 cells escaped proteolytic processing.
terminal processing remain unknown. Furthermore, theFurthermore, in contrast to the effects of amino-terminal pro-
addition of custom-designed tags to recombinant PR3peptide deletion on PR3-ANCA binding, carboxy-terminal
modifications (deletion and additions) did not significantly af- (rPR3) variants could facilitate studies of intracellular
fect recognition by PR3-ANCA. processing, purification of rPR3, and subsequent use of
Conclusions. This expression system is ideally suited for the such rPR3 variants in solid phase assays for PR3-ANCAexpression of custom-designed carboxy-terminal rPR3 vari-
detection, as labeled competitors in inhibition assays, orants, and major conformational effects of carboxy-terminal
as ligands for molecular and cell binding studies. There-modifications seem unlikely.
fore, this study was designed to determine whether 293
cells secrete rPR3 variants with intact carboxy-terminal
propeptide extensions, and to evaluate the effect of dif-Anti-neutrophil cytoplasmic antibodies (ANCA) caus-
ing cytoplasmic immunofluorescence (C-ANCA) on eth- ferent carboxy-terminal modifications of rPR3 on the
anol-fixed neutrophils are highly specific for the small recognition by PR3-ANCA.
vessel vasculitides Wegener’s granulomatosis (WG), mi-
croscopic polyangiitis and, organ limited variants like
METHODSpauci-immune necrotizing glomerulonephritis [1, 2]. Neu-
Unless specified otherwise, all reagents were purchased
from Sigma Chemical Co. (St. Louis, MO, USA). Purified
Key words: ANCA, proteinase 3, small vessel vasculitis, Wegener’s
neutrophil PR3 (PMN-PR3) was purchased from Athensgranulomatosis, pauci-immune glomerulonephritis, 293 cells, recombi-
nant PR3. Research and Technology (Athens, GA, USA). The
monoclonal anti-PR3 antibody (mAb), MCPR3-2, hasReceived for publication April 17, 2002
been characterized previously [10]. The polyclonal rabbitand in revised form July 15, 2002
Accepted for publication September 20, 2002 anti-PR3 antibody was generated by immunization with
PMN-PR3. The mAb directed against the c-myc poly- 2003 by the International Society of Nephrology
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Fig. 1. Schematic diagram of cDNA constructs. The nucleotide sequence (small letters) is listed above the amino acid sequence. Stop codons are
underlined. The single letter code (capital letters) and the bovine chymotrypsinogen numbering system for serine proteases of the trypsin family
are used to identify amino acid residues and their positions. S195A indicates the substitution of the active site serine at position 195 by an alanine
residue. 244R indicates the arginine residue after which the carboxy-terminal proheptapeptide of proteinase 3 (PR3) is cleaved. Abbreviations
are: L, linker peptide; GFP, green fluorescence protein.
peptide (cmyc) and rabbit polyclonal anti-green fluores- construct rPR3-cmyc codes for an rPR3 variant carrying
a carboxy-terminal 21 residue extension following Pro-cent protein (GFP) antibody were purchased from In-
vitrogen (San Diego, CA, USA). 251 of PR3, which consists of the c-myc peptide followed
by six His-residues. This extension is recognized by anti-C-ANCA positive sera (titer range 1:4 to 1:256) were
obtained from 58 patients with biopsy-proven WG evalu- bodies to c-myc and poly-His. The poly-His extension is
designed to facilitate purification of proteins by bindingated at Mayo Clinic (34% had active disease at the time
of sampling). All 58 samples were PR3-ANCA positive to nickel-resins.
The construct rPR3-GFP was generated by PCR reac-by capture enzyme-linked immunosorbent assay (ELISA)
using PMN-PR3 as the substrate. Their use for this study tion using the primers US203 5-AAGCTTCCCACC
ATGGCTCACC-3 (sense) and US204 5-CGGGGCGwas approved by the Institutional Review Board at Mayo
Clinic. GCCCTTGGCCT-3 (antisense) and cloning the PCR
product into the pcDNA3.1/CT-GFP-TOPO vector us-Figure 1 shows the rPR3 cDNA constructs used. Amino
acid numbers are based on tertiary structure similarities ing the CT-GFP Fusion TOPO TA Expression Kit (In-
vitrogen). The construct codes for a fusion protein con-with bovine chymotrypsinogen A apparent from the crys-
tal structure of human PR3 facilitating the sequence align- sisting of the 229 amino acid residues of PR3, 16 linker
residues, and the 239 residues of GFP. The carboxy-ment of similar serine proteases [11, 12]. The original
cDNA insert coding for wild-type rPR3 (rPR3) and those terminal GFP extension conveys autofluorescence of
tagged proteins facilitating the tracking of their expres-coding for the active site mutant, rPR3-S195A, and the
amino-terminal propeptide deletion mutant, -rPR3- sion and cellular localization.
The cDNA construct rPR3- was prepared using theS195A, as well as their expression in 293 cells have been
described elsewhere [5, 8]. For the generation of the Quick-Change Site-Directed Mutagenesis Kit (Stratagene,
La Jolla, CA, USA). The PCR primers US223 5-CCACGconstruct rPR3-cmyc, HindIII/XbaI restricted wild-type
rPR3 was used as the polymerase chain reaction (PCR) CTGCGCCGTTGAGAGGCCAAGGGCCGC-3 (sense)
and US224 5-GCGGCCCTTGGCCTCTCAACGGCGtemplate with the primers US124 5-AAGCTTCCCAC
CATGGCT-3 (sense) and US126 5-GGGCCCGGGG CAGCGTGG-3 (antisense) were designed to replace the
codon for Val-245 with a translation stop codon after resi-CGGC-3 (antisense), generating an ApaI restriction site
overhang adjacent to the codon for residue Pro-251. This due Arg-244, the presumed cleavage site of the carboxy-
terminal PR3 propeptide [4].PCR product was subcloned into HindIII/ApaI restricted
expression vector pcDNA3/myc-His (Invitrogen). The Adherent 293 cells (American Type Tissue Culture,
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Fig. 2. (A) Western blots of conditioned me-
dia of 293 cells expressing wild-type rPR3
(lane 1), rPR3- (lane 2), rPR3-cmyc (lane 3)
and rPR3-GFP (lane 4). Proteins were sepa-
rated by SDS-PAGE (12% gel) under non-
reducing condition and probed with the mono-
clonal antibodies MCPR3-2 (anti-PR3), anti-
myc (anti-cmyc), and the polyclonal rabbit
anti-GFP (anti-GF) antibody. The rPR3 vari-
ants carry the expected carboxy-terminal ex-
tensions indicating the 293 cells secrete car-
boxy-terminally unprocessed rPR3 into the
media supernatant. (B) The capture ELISA,
using MCPR3-2 as the capturing antibody and
rabbit polyclonal anti-PR3 as the detection
antibody, was used to quantify the rPR3 vari-
ants in the conditioned media. Shown are the
means  SEM of three independent experi-
ments for serial dilutions of conditioned me-
dia containing wild-type rPR3 (), rPR3- (),
rPR3-cmyc (), and rPR3-GFP (), in compar-
ison to known concentrations of PMN-PR3 ().
Rockville, MD, USA) grown to confluence were trans- GFP secreted into the media supernatants indeed carry
the expected extensions.fected using the calcium phosphate precipitation method
To determine the affinity of the rPR3 variants for the(Stratagene) [8]. Stable transfected 293 cell clones ex-
capturing mAb MCPR3-2, to quantify levels of rPR3pressing rPR3-, rPR3-cmyc and rPR3-GFP were se-
secretion from different clones, and to identify optimallected in the presence of genticin (Gibco, Grand Island,
dilutions of media supernatants to be used in the captureNY, USA). Clones were screened for expression of rPR3
ELISA for PR3-ANCA detection, serial dilutions of me-by immunoblot with MCPR3-2.
dia supernatants were tested in the capture ELISA andFor immunoblotting, proteins were separated by 12%
compared to known quantities of PMN-PR3 (Fig. 2B).sodium dodecyl sulfate-polyacrylamide gel electrophore-
Only the dilution curve of rPR3-GFP had a slightly dif-sis (SDS-PAGE) under non-reducing conditions, trans-
ferent slope from those of PMN-PR3 and the other threeferred to nitrocellulose membranes, and probed with
rPR3 variants, suggesting some effect of this large molec-MCPR3-2, anti-cmyc, anti-GFP. Bound antibodies were
ular extension on the binding to MCPR3-2. The 293 celldetected using goat anti-mouse and goat anti-rabbit (Bio-
clones expressed 0.25 g rPR3, rPR3-, rPR3-cmyc, andRad, Richmond, CA, USA) HRP-conjugated secondary
0.04 g of rPR3-GFP per mL of serum-free media super-antibodies and the ECL chemiluminescence system
natants per 24 hours.(Amersham, Arlington Heights, IL, USA).
Of the 58 serum samples one was negative in the assayFor the quantification of rPR3 variants in 293 cell
when the mature conformation -rPR3-S195A lackingmedia supernatants a capture ELISA with MCPR3-2 as
the amino-terminal propeptide was used as target anti-capturing antibody and polyclonal rabbit anti-PR3 for
gen. This sample had a low C-ANCA titer of 1:4 and adetection of bound rPR3 was used [10]. PR3-ANCA
borderline positive result in the capture ELISA withreactivity with the different rPR3 variants was measured
PMN-PR3 (O.D. 0.104). As observed in two previousalso by capture ELISA [10]. A net absorbance of0.100
series [8, 9], most of the PR3-ANCA sera included in thiswas considered negative in this assay [8–10].
series displayed lower reactivity with amino-terminally
unprocessed rPR3-S195A compared with-rPR3-S195A
RESULTS (Fig. 3A). In contrast, the effect of carboxy-terminal
Expression of the carboxy-terminal rPR3 variants by propetide deletion on PR3-ANCA binding was less pro-
stable 293 cells clones was evaluated by immunoblot nounced (Fig. 3B). It resulted in a slight gain of binding
using MCPR3-2 for rPR3 detection (Fig. 2A). As ex- of most PR3-ANCA, and a significant correlation (R2 
pected from a seven amino acid difference, the rPR3- 0.83, P  0.0001) was preserved. The best correlation
has an apparent molecular mass that is about 1 kD lower was detected between rPR3 and rPR3-cmyc (R2  0.97,
than that of rPR3. Probing the blotted proteins with anti- P  0.0001; Fig. 3C), indicating that a small carboxy-
terminal extension does not affect PR3-ANCA binding.cmyc and anti-GFP confirmed that rPR3-cmyc and rPR3-
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Fig. 3. Scatterplots of absorbance values ob-
tained by capture ELISA with different rPR3
variants. (A) Most serum samples showed a
lower reactivity with amino-terminally unpro-
cessed rPR3-S195A than with the amino-ter-
minally processed -rPR3-S195A. The PR3-
ANCA reactivities with rPR3-, rPR3-cmyc,
and rPR3-GFP in comparison to that with
wild-type rPR3 are shown in panels B, C, and
D, respectively. A net absorbance of 0.1 is
considered negative in this assay and is indi-
cated by solid lines. The dashed diagonal lines
indicate equal reactivities with both target an-
tigens. The significance of correlations was an-
alyzed using the F test for linear regression.
Two-sided P values of 0.05 were considered
significant.
The carboxy-terminal addition of GFP had some effect tional and functional effects on the molecule [8, 18, 19].
In contrast, the impact of carboxy-terminal processingon PR3-ANCA binding (Fig. 3D), but again, a significant
correlation with the binding to wild-type rPR3 was pre- of PR3 has not been studied extensively. Here we have
demonstrated that custom-designed carboxy-terminalserved (R2  0.79, P  0.0001). In contrast to the effect
of the carboxy-terminal deletion the observed differ- molecular tags can serve as useful tools for studies of
rPR3 processing. However, conformational changes ofences in binding were not unidirectional. Only seven
samples displayed 50% reduced binding compared to rPR3 induced by carboxy-terminal modifications of the
molecule could have profound effects on the ability towild-type rPR3, suggesting that the binding of most PR3-
bind ligands. Consequently, in order to interpret theANCA is not sterically hindered by this large addition.
results of experiments obtained with carboxy-terminally
modified rPR3 molecules appropriately, the effect of such
DISCUSSION modifications on conformation needs to be known. To
Our results indicate that the renal epithelial cell line this end, we studied the described four carboxy-terminal
293 secretes carboxy-terminally unprocessed rPR3 into rPR3 variants. The highly conformation-sensitive bind-
the media supernatants. Consequently, this expression ing of PR3-ANCA is the most sensitive surrogate marker
system is suitable for the generation of rPR3 variants of conformational changes induced by mutational alter-
with custom-designed carboxy-terminal modifications. ations of the PR3 amino-acid sequence. Therefore, it
Unlike the amino-terminal activation dipeptide motif, was used as a probe to identify significant conformational
the carboxy-terminal extensions of the various neutro- changes.
phil serine proteases from different species are not con- The data indicate that, in contrast to the conforma-
served [12–17]. The cleavage of the amino-terminal pro- tional effects of the cleavage of the amino-terminal pro-
peptide allows the formation of a salt bridge between dipeptide, the deletion of the carboxy-terminal pro-
Ile-16 and Asp-194 residues of the trypsin-like neutrophil heptapeptide of PR3 has little conformational impact,
implying that its functional role is likely to be minimal.serine proteases including PR3 with profound conforma-
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